title: Journey in guidelines for lipid management: From adult treatment panel (ATP)-I to ATP-III and what to expect in ATP-IV.
abstract: Adult Treatment Panel (ATP), an expert panel to supervise cholesterol management was set up under the aegis of National Cholesterol Education Program (NCEP) in 1985. Since then NCEP-ATP has been revising and framing guidelines to enable clinician to deliver better treatment to cardiovascular patients and to educate general people. As a result, considerable reduction in cardiovascular related deaths has been observed in recent times. All three ATP guidelines viz. ATP-I, ATP-II and ATP-III have targeted low density lipoprotein as their primary goal. The ATP-III guideline was updated in the light of evidences from 5-major clinical trials and was released in 2004. It added therapeutic lifestyle changes, concept of risk equivalents, Framingham CHD-risk score non-high density lipoprotein cholesterol (non-HDL-C) as secondary target and gave strong emphasis on metabolic risk factors. The earlier treat-to-target paradigm faced fierce criticism from clinicians across the globe because of insufficient proof of safety and benefits of treating patients with respect to an individual's low density lipoprotein (LDL) level. Further, demonstration of non-HDL-C and total cholesterol/HDL-C ratio as strong predictors of overall cardiovascular risk foresees new guidelines. A tailored-treatment approach was suggested instead of LDL-C target based treatment approach which was soundly based on direct clinical trials evidences and proposes treatment based on individual's overall 5- to 10-year cardiovascular risk irrespective of LDL-C level, leading to lower number of people on high dose/s of statins. Recent report of the Cholesterol Treatment Trialist's Collaborators meta-analysis strongly supported primary prevention of LDL with statins in low risk individuals and showed that its benefits completely outweighed its known hazards. Markers other than LDL-C like apolipoprotein B, non-HDL-C and total cholesterol/HDL-C ratio would take precedence in the risk assessment and strong emphasis would be given on tailored-treatment approach in the upcoming ATP-IV guideline.
authors: Department of Endocrinology, S.L. Raheja Hospital for Diabetes and All India Institute of Diabetes, Mumbai, India.
authors: P G
authors: PG
authors: Talwalkar
authors: C G
authors: CG
authors: Sreenivas
authors: Ashish
authors: A
authors: Gulati
authors: Hemang
authors: H
authors: Baxi
keywords: Adult treatment panel; coronary heart disease; low-density lipoprotein cholesterol
references: Ann Intern Med. 2010 Jan 19;152(2):69-77
references: 20083825
references: Chest. 2001 Sep;120(3):979-88
references: 11555537
references: Circulation. 1991 Jan;83(1):356-62
references: 1984895
references: Lancet. 2012 Aug 11;380(9841):581-90
references: 22607822
references: Am J Manag Care. 2003 Feb;9(2 Suppl):S39-58
references: 12597240
references: Lancet. 2010 Feb 27;375(9716):735-42
references: 20167359
references: BMJ. 2010 Jul 28;341:c3531
references: 20667950
references: Lancet. 2002 Nov 23;360(9346):1623-30
references: 12457784
references: JAMA. 2002 Dec 18;288(23):2998-3007
references: 12479764
references: Cardiol Clin. 2003 Aug;21(3):393-8
references: 14621453
references: Circ Cardiovasc Qual Outcomes. 2011 May;4(3):337-45
references: 21487090
references: JAMA. 1999 Dec 1;282(21):2051-7
references: 10591388
references: Lancet. 2007 Nov 24;370(9601):1781-90
references: 17559928
references: Ann Epidemiol. 1992 Jan-Mar;2(1-2):23-8
references: 1342260
references: Circulation. 2002 Dec 17;106(25):3143-421
references: 12485966
references: Circulation. 2004 Jul 13;110(2):227-39
references: 15249516
references: Circulation. 2004 Jun 15;109(23 Suppl 1):III8-14
references: 15198960
references: Clin Chem. 2002 Jan;48(1):11-7
references: 11751533
references: Am J Manag Care. 2007 Mar;13(3):126-8
references: 17335355
references: Ann Intern Med. 2008 May 6;148(9):656-61
references: 18458278
references: J Hypertens. 1998 Oct;16(10):1407-14
references: 9814610
references: Circulation. 2008 Nov 25;118(22):2243-51, 4p following 2251
references: 18997194
references: Arch Intern Med. 1988 Jan;148(1):36-69
references: 3422148
references: JAMA. 1996 Sep 18;276(11):882-8
references: 8782637
references: Lancet. 2003 Apr 5;361(9364):1149-58
references: 12686036
references: Clin Cardiol. 2002 Mar;25(3):89-90
references: 11890375
references: Am J Cardiol. 2005 Aug 22;96(4A):53E-59E
references: 16098845
references: JAMA. 2001 May 16;285(19):2486-97
references: 11368702
references: Ann Intern Med. 1996 Mar 1;124(5):515-7
references: 8602714
references: Circ Cardiovasc Qual Outcomes. 2012 Jan;5(1):2-5
references: 22253366
references: Circulation. 1998 Apr 21;97(15):1436-9
references: 9576422
references: JAMA. 1993 Jun 16;269(23):3015-23
references: 8501844
references: Ann Intern Med. 2006 Oct 3;145(7):520-30
references: 17015870
references: Lancet. 2010 Nov 13;376(9753):1670-81
references: 21067804
references: N Engl J Med. 2004 Apr 8;350(15):1495-504
references: 15007110